TABLE 103Comparison of results of PenTAG's and BMS's models for dasatinib versus HDI

ResultPenTAGBMS
Dasatinib
Years on treatment (undiscounted, mean)6.58.8
Years in CP (undiscounted, mean)10.58.8
OS (undiscounted, mean)13.49.7
Drug cost (£) (discounted, mean)161,000195,000
Dose intensity (%) (median)100100
HDI
Years on treatment (undiscounted, mean)2.78.8
Years in CP (undiscounted, mean)10.58.8
OS (undiscounted, mean)12.49.8
Drug cost (£) (discounted, mean)88,900243,000
Dose intensity (%) (median)92100
Incremental results
Incremental total costs (£) (discounted)48,900−50,545
Incremental total QALYs (discounted)0.540.13
ICER (£/QALY)91,500Dasatinib dominates HDI

From: 5, Cost-effectiveness: chronic myeloid leukaemia in chronic phase

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.